FDA Issues Warning Letter For Emergent Bio's Manufacturing Facility

The FDA issued a warning letter to Emergent BioSolutions Inc (NYSE:EBS), citing certain deficiencies at the company's troubled manufacturing facility in Baltimore, Maryland.
The FDA pointed to equipment cleaning and maintenance deficiencies to prevent drug product contamination.
Reuters reported that the agency also recommended that the company review its quality control process.
Related: Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract.
Emergent had said the FDA had last inspected its facility at Camden in February earlier this month and was waiting for the agency's feedback.
The contract drugmaker said it was also conducting additional reviews with a third party in the meantime to ensure "delivery of medically necessary products."
Also Read: Emergent BioSolutions Posts Q2 Loss On Lower Sales, Q3 Forecasts Below Consensus.
Price Action: EBS shares closed at $30.50 on Friday.